Literature DB >> 23718666

[Prognostic factors for cervical cancer].

L Mouková1, R Nenutil, P Fabian, J Chovanec.   

Abstract

Standardized gynecological oncological therapeutical guidelines are based on ordinary predictive factors, such as depth of stromal invasion, histopathological type of tumor, lymphovascular space invasion, lymph node metastases. Unfortunately, the power of these prognostic factors is not able to determine the safety of this procedure in the relation to disease recurrence in a group of patients who are indicated for conservative operations. This is the appropriate area for new, especially biomolecular prognostic factors (proteins: p63, TAp63, p16, p21, p27, COX-2, genes: hTERC, MYCC). Moreover, comprehensive evaluation of cervical cancer prognostic factors and assessment of new biomarkers of cancer can ease prediction of risk of spread outside primary localization and determine probability of disease recurrence. This information can help to individualize surgical, radiotherapeutic and chemotherapeutic treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23718666     DOI: 10.14735/amko201383

Source DB:  PubMed          Journal:  Klin Onkol        ISSN: 0862-495X


  3 in total

1.  URG4 overexpression is correlated with cervical cancer progression and poor prognosis in patients with early-stage cervical cancer.

Authors:  Lan Zhang; He Huang; Longjuan Zhang; Teng Hou; Shu Wu; Qidan Huang; Libing Song; Jihong Liu
Journal:  BMC Cancer       Date:  2014-11-26       Impact factor: 4.430

2.  TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer.

Authors:  Rui Xu; Jingye Hu; Tiansong Zhang; Chao Jiang; Hui-Yun Wang
Journal:  Oncotarget       Date:  2016-05-10

Review 3.  Electrical stimulation on adverse events caused by chemotherapy in patients with cervical cancer: A protocol for a systematic review of randomized controlled trial.

Authors:  Peng-Hui Dou; Dan-Feng Zhang; Cui-Hong Su; Xiao-Li Zhang; Ying-Jie Wu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.